Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
Eli Lilly acquires Calytrix Bio for up to $1.5B in rare blood cancer push
00

Eli Lilly acquires Calytrix Bio for up to $1.5B in rare blood cancer push

Nov 16, 2026

Eli Lilly has agreed to acquire Wellesley-based biotech startup Calytrix Bio for up to $1.5 billion, expanding its footprint in rare blood cancer treatments. The transaction includes an undisclosed upfront cash payment and clinical milestone payouts. Calytrix Bio's lead program targets myeloproliferative neoplasms like myelofibrosis and essential thrombocythemia using a biparatopic antibody targeting CALR gene mutations. The deal represents Eli Lilly's 15th acquisition of 2026.

Terms of the Calytrix acquisition

  • ▪Eli Lilly agreed to acquire Wellesley, Massachusetts-based biotech startup Calytrix Bio Inc. for up to $1.5 billion
  • ▪The acquisition agreement between Eli Lilly and Calytrix Bio Inc. includes an undisclosed upfront cash payment and subsequent payouts tied to clinical trial and regulatory milestones

Statements from Calytrix Bio leadership

  • ▪Calytrix Bio Inc. President and Chief Executive Officer Brad Prosek stated that Calytrix Bio Inc. looks forward to Eli Lilly advancing the treatment program through clinical trials
  • ▪Calytrix Bio Inc. President and Chief Executive Officer Brad Prosek stated that Calytrix Bio Inc. was founded on the belief that patients with myeloproliferative neoplasms deserve therapies that do more than manage symptoms

Calytrix's lead blood cancer treatment

  • ▪Calytrix Bio Inc. is developing an experimental biparatopic antibody designed to bind to two separate sites on mutated CALR cell-surface proteins while sparing healthy tissue
  • ▪Calytrix Bio Inc.'s lead candidate is an early-stage antibody treatment for essential thrombocythemia and myelofibrosis

Characteristics and current treatments of myeloproliferative neoplasms

  • ▪Myeloproliferative neoplasms are rare blood cancers originating in bone marrow that occur when the body overproduces red blood cells, leading to bone marrow scarring and blood clots
  • ▪Existing therapies for myeloproliferative neoplasms include blood transfusions and JAK inhibitor drugs such as Incyte's Jakafi, which manage disease symptoms rather than targeting underlying mutations

Eli Lilly's 2026 acquisition strategy

  • ▪Eli Lilly has pursued company acquisitions throughout 2026 to expand into oncology, hematology, and autoimmune diseases beyond its blockbuster diabetes and weight-loss franchise
  • ▪Eli Lilly's acquisition of Calytrix Bio Inc. follows Eli Lilly's purchase of Ajax Therapeutics earlier in 2026 to expand into rare blood cancer treatments
  • ▪The purchase of Calytrix Bio Inc. on November 16, 2026 marked Eli Lilly's 15th announced company acquisition of 2026, bringing its total 2026 acquisition spending to over $30 billion

3 sources

BioPharma Dive
Lilly adds to buyout streak with $1.5B purchase of startup Calytrix
View source article
Reuters
Lilly to buy Calytrix Bio for up to $1.5 billion | Reuters
View source article
Bloomberg
Eli Lilly to Acquire Calytrix Bio in Deal Worth Up to $1.5 Billion
View source article

Story comments

Loading comments…

Related entities

MyelofibrosisWellesley

Topics

Mergers & acquisitions (M&A)Biotech startupMergers and acquisitionsEli LillyDrug developmentHematology & Blood CancersCancer & OncologyPharmaceutical IndustryRare diseases